Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada received approval from Health Canada of CABOMETYX (cabozantinib) tablets for the treatment...
Zosano Pharma Completes Manufacture of M207 Registration Batches
Zosano Pharma (NASDAQ:ZSAN) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary...
Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018
Scilex Pharmaceuticals a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE) announced that the Wholesale Acquisition Cost (WAC) for ZTlido (lidocaine topical...
Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy
Molecular Templates (Nasdaq:MTEM) announced an agreement with Takeda Pharmaceutical for the joint development of CD38-targeted engineered toxin bodies (ETBs) for...
Cynata’s Cymerus MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study
Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX:CYP) is pleased to announce data from a preclinical model demonstrating...
BioSig Technologies to Commence Trading on the Nasdaq
BioSig Technologies (OTCQB:BSGM, OTCQB:BSGMD), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet...
Canntab Exceeds All-Time High Trading Prices and Grants Options
Canntab Therapeutics (CSE:PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form,...
CBD Beverage Hits Mainstream via Pepsi Independent Distributors
Xanthic Beverages, an Oregon-based beverage company, recently unveiled their flagship product, and it's disruptive for the entire cannabis industry.
Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials
Canntab Therapeutics (CSE:PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of...
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge
Cancer Genetics (Nasdaq:CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and...